Lung Cancer Clinical Trials & Research at Providence Medical Group

The two main types of lung cancer are non-small cell lung cancer and small cell lung cancer. The types are based on the way the cells look under a microscope. Non-small cell lung cancer is much more common than small cell lung cancer. Tobacco smoking is the most common cause of lung cancer.

Providence Medical Group is currently enrolling patients for the following lung cancer clinical trials:

Non-Small Cell Lung Cancer
Small Cell Lung Cancer


A Phase lb Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2+) (DESTINY-Lung03)

Treatment agent: Trastuzumab deruxtecan + durvalumab, carboplatin, or pemetrexed
PI: Ian Anderson, MD
Study Coordinator: Melissa Phillips // Melissa.Phillips2@stjoe.org// (707) 521-3833 ext. 1313
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT03328026
Sponsor: AstraZeneca


Study to Assess the Effect of PF_06946860 on Appetite Following Subcutaneous Administration to Patients with Anorexia and Advanced Cancer

Treatment agent: PF-06946860
PI: Sara Keck, MD
Study Coordinator: Tracy Foster
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04803305?term=PF-06946860&draw=2&rank=2
Sponsor: Pfizer


A Phase III, Randomized, Multicenter, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Comination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA)

Treatment agent: Chemotherapy + Osimbertinib or placebo
PI: Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links: A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer - Full Text View - ClinicalTrials.gov
Sponsor: AstraZeneca


Non-Small Cell Lung Cancer

A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)

Treatment agent: Canakinumab or Placebo
PI: Ian Anderson, MD
Study Coordinator: Tracy Foster
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04642469?term=04642469&draw=2&rank=1
Sponsor: Novartis Pharmaceuticals


A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Treatment agent: MRTX849 + pembrolizumab
PI: Manasa Vulchi, MD
Study Coordinator: Tracy Foster
Resources and Links: clinicaltrials.gov NCT No: NCT04613596
Sponsor: Mirati Therapeutics, Inc.


Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)

Treatment agent: Zimberelimab with or without domvanalimab and/or etrumadenant
PI: Ian Anderson, MD
Study Coordinator: Camille Shaffer
Resources and Links: clinicaltrials.gov NCT No: NCT04262856
Sponsor: Arcus Biosciences, Inc.


A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MeRmaiD-1)

Treatment agent: Durvalumab + chemotherapy
PI: Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links: clinicaltrials.gov NCT No: NCT04385368
Sponsor: AstraZeneca


A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

Treatment agent: Trastuzumab Deruxtecan
PI: Ian Anderson, MD
Study Coordinator: Tracy Foster
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT05048797
Sponsor: AstraZeneca


A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Treatment agent: Ociperlimab, Tislelizumab, Pembrolizumab
PI: Ian Anderson, MD
Study Coordinator: Camille Shaffer/ Camille.Shaffer@stjoe.org / (707) 521-3809
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04746924?term=NCT04746924&draw=2&rank=1
Sponsor: BeiGene


A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8)

Treatment agent: Durvalumab + Domvanalimab
PI: Ian Anderson, MD
Study Coordinator: Tracy Foster
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT05211895?term=NCT05211895&draw=2&rank=1
Sponsor: AstraZeneca


A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Treatment agent: Sapanisertib
PI: Ian Anderson, MD
Study Coordinator: Tracy Foster //Teresa.Lund@stjoe.org// (707) 521-3803
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT05275673?term=NCT05275673&draw=2&rank=1
Sponsor: Calithera


A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Treatment agent: KIN-2787
PI: Ian Anderson, MD
Study Coordinator: Tracy Foster //Teresa.Lund@stjoe.org// (707) 521-3803
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT04613596?term=NCT04613596&draw=2&rank=1
Sponsor: Mirati Therapeutics, Inc.


Phase 1 Study of Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

Treatment agent: Tipifarnib and Osimertinib
PI: Ian Anderson, MD
Study Coordinator: Tracy Foster //Teresa.Lund@stjoe.org// (707) 521-3803
Sponsor: Kura


Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab for NSCLC With KRAS G12C Mutation KRYSTAL-7

Treatment agent: MRTX849
PI: Ian Anderson, MD
Study Coordinator: Tracy Foster //Teresa.Lund@stjoe.org// (707) 521-3803
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04913285?term=NCT04913285&draw=2&rank=1Sponsor: Kura


Small Cell Lung Cancer

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Another Anti-cancer Therapy for Treatment of Recurrent (Non-small Cell) Lung Cancer

Treatment: GEN1046 alone or with Pembrolizumab
PI: Ian Anderson, MD
Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT05117242
Sponsor: Genmab


A Phase II, Open-label, Single-arm Study of Berzosertib (M6620) in Combination With Topotecan in Participants With Relapsed Platinum-resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

Treatment agent: Berzosertib, Topotecan Hydrochloride
PI: Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04768296?term=DDRiver&draw=2&rank=1
Sponsor: EMD Serono


Seer-020201 (Pulmonary Nodules)

Treatment: Durvalumab + Tremelimuab, Durvalumab, and Placebo
PI: Manasa Vulchi, MD
Study Coordinator: Melissa​
NCT – NA


A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation

Treatment: MRTX849, Docetaxel
PI: Ian Anderson, MD
Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04685135?term=krystal-12&draw=2&rank=1
Sponsor: Mirati Therapeutics


A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy (MERMAID-2) (AstraZeneca D910MC00001 MERMAID 2)

Treatment: Durvalumab or placebo
PI: Ian Anderson, MD
Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04642469?term=04642469&draw=2&rank=1
Sponsor: AstraZeneca


A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) (Novartis CACZ885T2301 CANOPY )

Treatment: Canakinumab or Placebo
PI: Ian Anderson, MD
Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT03447769?term=03447769&draw=2&rank=1
Sponsor: Novartis Pharmaceuticals


A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation (Mirati 849-012 KRYSTAL-12 )

Treatment: MRTX849, Docetaxel
PI: Ian Anderson, MD
Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04685135?term=krystal-12&draw=2&rank=1
Sponsor: Mirati Therapeutics, Inc.


A Phase III, Randomised, Controlled, Multi-centre, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA)

Treatment: Chemotherapy + Osimbertinib or placebo
PI: Ian Anderson, MD
Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04351555?term=NeoADAURA&draw=2&rank=1
Sponsor:AstraZeneca


A Study to Evaluate the Efficacy and Safety of HLX10 in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Treatment: HLX10
PI: Ian Anderson, MD
Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT05353257?term=NCT05353257&draw=2&rank=1
Sponsor: Henlius Biotech, Inc


Our Providers

Our Locations